Achillion Pharmaceuticals (ACHN) 12.17 $ACHN
Most active Nasdaq-traded stocks
AP - Fri Sep 05, 2:45PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at 1 p.m.:
Nasdaq stocks posting largest percentage decreases
AP - Fri Sep 05, 2:45PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
Biotech Stock Mailbag: Achillion, Ariad Revisited, Endocyte
at The Street - Fri Sep 05, 7:55AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
Why Achillion Pharmaceuticals (ACHN) Stock Might be a Great Pick - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 7:33AM CDT
Achillion Pharmaceuticals belongs to the Medical industry, is a decent pick as it witnessed solid earnings estimate revision activity with a favorable Zacks Industry Rank.
Market Maker Surveillance Report. GILD, GE, SLM, ACHN, WU, SREV, Bullishly Biased Price Friction For Wednesday, September 3rd 2014
M2 - Thu Sep 04, 10:02AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Wednesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Wednesday there were 4918 companies with "abnormal" market making, 2306 companies with positive Friction Factors and 2830 companies with negative Friction Factors. Here is a list of the top companies with Abnormal Price Friction (bullish bias) in their stock prices. This means that there was more selling than buying in the stocks and their stock prices rose. GILEAD SCIENCES, INC. (NASDAQ:GILD), General Electric Co (NYSE:GE), SLM Corp (NASDAQ:SLM), Achillion Pharmaceuticals Inc (NASDAQ:ACHN), Western Union Co (NYSE:WU), SERVICESOURCE INTERNATIONAL INCORPORATED (NASDAQ:SREV). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
'Mad Money' Lightning Round: I'm Taking Verizon Over AT&T
at The Street - Wed Sep 03, 5:00AM CDT
Cramer prefers Dow Chemicals to FMC and MGM Resorts to Las Vegas Sands.
Jim Cramer's 'Mad Money' Recap: The 2012 Stock Market All Over Again
at The Street - Tue Sep 02, 6:49PM CDT
Investors are dumping the industrial and technology stocks in favor of anything domestic, including health care, transportation, restaurants and entertainment, Cramer says.
Reveal Insider Trading for Facebook, Plug Power, Achillion Pharmaceuticals, Apple, Twitter, and Intel
PR Newswire - Tue Sep 02, 7:55AM CDT
Today, Insiderslab.com revealed the latest insider trading research for Facebook (NASDAQ: FB), Plug Power (NASDAQ: PLUG), Achillion Pharmaceuticals (NASDAQ: ACHN), Apple (NASDAQ: AAPL), Twitter (NYSE: TWTR), and Intel (NASDAQ:INTC). US stock investors can access these reports through the links below, including stock performance, insider trading signals, and visual results.
Four biotech takeover targets?
at Investor's Business Daily - Fri Aug 29, 5:58PM CDT
Following the news that Roche (RHHBY) is acquiring InterMune (ITMN) for $8.3 bil, other takeover talk has started to stir, leading to speculation that Achillion Pharmaceuticals (ACHN), Intercept Pharmaceuticals (ICPT), Puma Biotechnology (PBYI) and...
4 Biotechs That Might Be Bought Soon
at Investor's Business Daily - Fri Aug 29, 10:53AM CDT
The recent announcement that Roche (RHHBY) will buy InterMune (ITMN) for $8.3 billion brought new life to M&A speculation in the biotech industry, which had been relatively neglected as the buzz focused on tax-inversion deals by biopharmaceutical...
Biotech Stock Roundup: Biotechs Surge on InterMune Acquisition Deal, Focus on More M&As - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Aug 27, 9:32AM CDT
Roche's agreement to acquire InterMune has raised hopes for more such deals in the biotech sector.
The Zacks Analyst Blog Highlights: Roche, InterMune, Achillion Pharmaceuticals, Puma Biotechnology and Intercept Pharmaceuticals
PR Newswire - Wed Aug 27, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Roche (OTC:RHHBY-Free Report), InterMune (Nasdaq:ITMN-Free Report), Achillion Pharmaceuticals (Nasdaq:ACHN-Free Report), Puma Biotechnology (NYSE
BYI-Free Report) and Intercept Pharmaceuticals (Nasdaq:ICPT-Free Report).
Achillion Pharmaceuticals (ACHN) Jumps: Stock Adds 9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Aug 27, 7:37AM CDT
Achillion Pharmaceuticals, Inc. (ACHN) was a big mover last session, as the company saw its shares rise 9% on the day.
Achillion Pharmaceuticals (ACHN) Stock Hits New One-Year High
at The Street - Tue Aug 26, 11:10AM CDT
Achillion Pharmaceuticals (ACHN) touched another 52-week high of $12 on Tuesday after UBS tabbed the company as a possible takeover target.
3 Biotechs Surging Following InterMune Takeover - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 26, 10:07AM CDT
InterMune 's (ITMN) impending acquisition by Roche (RHHBY) caused many mid-cap biotechs to rise.
Most active Nasdaq-traded stocks
AP - Fri Sep 05, 2:45PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at 1 p.m.:
Nasdaq stocks posting largest percentage decreases
AP - Fri Sep 05, 2:45PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
Biotech Stock Mailbag: Achillion, Ariad Revisited, Endocyte
at The Street - Fri Sep 05, 7:55AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
Why Achillion Pharmaceuticals (ACHN) Stock Might be a Great Pick - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 7:33AM CDT
Achillion Pharmaceuticals belongs to the Medical industry, is a decent pick as it witnessed solid earnings estimate revision activity with a favorable Zacks Industry Rank.
Market Maker Surveillance Report. GILD, GE, SLM, ACHN, WU, SREV, Bullishly Biased Price Friction For Wednesday, September 3rd 2014
M2 - Thu Sep 04, 10:02AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Wednesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Wednesday there were 4918 companies with "abnormal" market making, 2306 companies with positive Friction Factors and 2830 companies with negative Friction Factors. Here is a list of the top companies with Abnormal Price Friction (bullish bias) in their stock prices. This means that there was more selling than buying in the stocks and their stock prices rose. GILEAD SCIENCES, INC. (NASDAQ:GILD), General Electric Co (NYSE:GE), SLM Corp (NASDAQ:SLM), Achillion Pharmaceuticals Inc (NASDAQ:ACHN), Western Union Co (NYSE:WU), SERVICESOURCE INTERNATIONAL INCORPORATED (NASDAQ:SREV). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
'Mad Money' Lightning Round: I'm Taking Verizon Over AT&T
at The Street - Wed Sep 03, 5:00AM CDT
Cramer prefers Dow Chemicals to FMC and MGM Resorts to Las Vegas Sands.
Jim Cramer's 'Mad Money' Recap: The 2012 Stock Market All Over Again
at The Street - Tue Sep 02, 6:49PM CDT
Investors are dumping the industrial and technology stocks in favor of anything domestic, including health care, transportation, restaurants and entertainment, Cramer says.
Reveal Insider Trading for Facebook, Plug Power, Achillion Pharmaceuticals, Apple, Twitter, and Intel
PR Newswire - Tue Sep 02, 7:55AM CDT
Today, Insiderslab.com revealed the latest insider trading research for Facebook (NASDAQ: FB), Plug Power (NASDAQ: PLUG), Achillion Pharmaceuticals (NASDAQ: ACHN), Apple (NASDAQ: AAPL), Twitter (NYSE: TWTR), and Intel (NASDAQ:INTC). US stock investors can access these reports through the links below, including stock performance, insider trading signals, and visual results.
Four biotech takeover targets?
at Investor's Business Daily - Fri Aug 29, 5:58PM CDT
Following the news that Roche (RHHBY) is acquiring InterMune (ITMN) for $8.3 bil, other takeover talk has started to stir, leading to speculation that Achillion Pharmaceuticals (ACHN), Intercept Pharmaceuticals (ICPT), Puma Biotechnology (PBYI) and...
4 Biotechs That Might Be Bought Soon
at Investor's Business Daily - Fri Aug 29, 10:53AM CDT
The recent announcement that Roche (RHHBY) will buy InterMune (ITMN) for $8.3 billion brought new life to M&A speculation in the biotech industry, which had been relatively neglected as the buzz focused on tax-inversion deals by biopharmaceutical...
Biotech Stock Roundup: Biotechs Surge on InterMune Acquisition Deal, Focus on More M&As - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Aug 27, 9:32AM CDT
Roche's agreement to acquire InterMune has raised hopes for more such deals in the biotech sector.
The Zacks Analyst Blog Highlights: Roche, InterMune, Achillion Pharmaceuticals, Puma Biotechnology and Intercept Pharmaceuticals
PR Newswire - Wed Aug 27, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Roche (OTC:RHHBY-Free Report), InterMune (Nasdaq:ITMN-Free Report), Achillion Pharmaceuticals (Nasdaq:ACHN-Free Report), Puma Biotechnology (NYSE
BYI-Free Report) and Intercept Pharmaceuticals (Nasdaq:ICPT-Free Report). Achillion Pharmaceuticals (ACHN) Jumps: Stock Adds 9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Aug 27, 7:37AM CDT
Achillion Pharmaceuticals, Inc. (ACHN) was a big mover last session, as the company saw its shares rise 9% on the day.
Achillion Pharmaceuticals (ACHN) Stock Hits New One-Year High
at The Street - Tue Aug 26, 11:10AM CDT
Achillion Pharmaceuticals (ACHN) touched another 52-week high of $12 on Tuesday after UBS tabbed the company as a possible takeover target.
3 Biotechs Surging Following InterMune Takeover - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 26, 10:07AM CDT
InterMune 's (ITMN) impending acquisition by Roche (RHHBY) caused many mid-cap biotechs to rise.
